Why is Moderna, Inc. important to traders?
Learn how to trade Moderna shares with CFDs. Follow the comprehensive Moderna stock trading guide and spot the best trading opportunities at Capital.com.
Learn more about Moderna, Inc.Trade Moderna, Inc. - MRNA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 1.28 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 169.74 |
| Open* | 169.74 |
| 1-Year Change* | 11.82% |
| Day's Range* | 163.6 - 169.94 |
| 52 wk Range | 115.03-217.25 |
| Average Volume (10 days) | 3.46M |
| Average Volume (3 months) | 101.47M |
| Market Cap | 65.41B |
| P/E Ratio | 6.16 |
| Shares Outstanding | 384.18M |
| Revenue | 21.39B |
| EPS | 27.65 |
| Dividend (Yield %) | N/A |
| Beta | 1.64 |
| Next Earnings Date | Feb 23, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 169.74 | -0.06 | -0.04% | 169.80 | 169.92 | 169.74 |
| Feb 7, 2023 | 169.74 | -0.13 | -0.08% | 169.87 | 171.31 | 166.47 |
| Feb 6, 2023 | 169.87 | -0.57 | -0.33% | 170.44 | 173.76 | 169.00 |
| Feb 3, 2023 | 172.48 | -2.20 | -1.26% | 174.68 | 178.08 | 171.44 |
| Feb 2, 2023 | 174.68 | 1.75 | 1.01% | 172.93 | 177.42 | 169.96 |
| Feb 1, 2023 | 173.07 | -1.51 | -0.86% | 174.58 | 175.36 | 166.70 |
| Jan 31, 2023 | 174.43 | -5.44 | -3.02% | 179.87 | 179.91 | 173.18 |
| Jan 30, 2023 | 179.42 | -7.07 | -3.79% | 186.49 | 187.72 | 179.33 |
| Jan 27, 2023 | 188.38 | -2.63 | -1.38% | 191.01 | 192.94 | 187.70 |
| Jan 26, 2023 | 191.01 | -1.50 | -0.78% | 192.51 | 194.25 | 186.93 |
| Jan 25, 2023 | 190.98 | -2.88 | -1.49% | 193.86 | 194.56 | 189.13 |
| Jan 24, 2023 | 193.34 | -2.12 | -1.08% | 195.46 | 196.37 | 192.42 |
| Jan 23, 2023 | 195.46 | 3.49 | 1.82% | 191.97 | 198.08 | 190.00 |
| Jan 20, 2023 | 192.72 | 2.85 | 1.50% | 189.87 | 193.94 | 187.78 |
| Jan 19, 2023 | 189.96 | -5.88 | -3.00% | 195.84 | 196.46 | 189.55 |
| Jan 18, 2023 | 195.85 | -3.98 | -1.99% | 199.83 | 206.81 | 194.38 |
| Jan 17, 2023 | 199.84 | 10.34 | 5.46% | 189.50 | 205.64 | 186.66 |
| Jan 13, 2023 | 190.36 | 3.41 | 1.82% | 186.95 | 191.44 | 184.21 |
| Jan 12, 2023 | 186.95 | 2.23 | 1.21% | 184.72 | 188.39 | 178.60 |
| Jan 11, 2023 | 184.73 | -3.83 | -2.03% | 188.56 | 190.18 | 182.07 |
Moderna, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 108.396 | 205.825 | 135.068 | 60.209 | 803.395 | 18471 |
| Revenue | 108.396 | 205.825 | 135.068 | 60.209 | 803.395 | 18471 |
| Total Operating Expense | 332.167 | 475.181 | 548.334 | 605.929 | 1566.54 | 5175 |
| Selling/General/Admin. Expenses, Total | 57.45 | 64.722 | 94.252 | 109.62 | 188.267 | 567 |
| Research & Development | 274.717 | 410.459 | 454.082 | 496.309 | 1370.34 | 1991 |
| Operating Income | -223.771 | -269.356 | -413.266 | -545.72 | -763.144 | 13296 |
| Interest Income (Expense), Net Non-Operating | 8.603 | 13.36 | 23.958 | 32.241 | 16.125 | 1 |
| Net Income Before Taxes | -215.168 | -255.996 | -384.408 | -514.716 | -744.513 | 13285 |
| Net Income After Taxes | -216.211 | -255.916 | -384.734 | -514.021 | -747.064 | 12202 |
| Net Income Before Extra. Items | -216.211 | -255.916 | -384.734 | -514.021 | -747.064 | 12202 |
| Net Income | -216.211 | -255.916 | -384.734 | -514.021 | -747.064 | 12202 |
| Total Adjustments to Net Income | -14.103 | -13.925 | -17.123 | 0 | 0 | |
| Income Available to Common Excl. Extra. Items | -230.314 | -269.841 | -401.857 | -514.021 | -747.064 | 12202 |
| Income Available to Common Incl. Extra. Items | -230.314 | -269.841 | -401.857 | -514.021 | -747.064 | 12202 |
| Diluted Net Income | -230.314 | -269.841 | -401.857 | -514.021 | -747.064 | 12202 |
| Diluted Weighted Average Shares | 324.411 | 324.411 | 328.799 | 330.802 | 381.333 | 431 |
| Diluted EPS Excluding Extraordinary Items | -0.70994 | -0.83179 | -1.2222 | -1.55386 | -1.95909 | 28.3109 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Diluted Normalized EPS | -0.70994 | -0.83179 | -1.2222 | -1.55386 | -1.95909 | 28.3109 |
| Other, Net | 4.9 | -1.237 | 2.506 | -12 | ||
| Cost of Revenue, Total | 7.933 | 2617 | ||||
| Gross Profit | 795.462 | 15854 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 1937 | 4354 | 4969 | 7211 | 6066 |
| Revenue | 1937 | 4354 | 4969 | 7211 | 6066 |
| Cost of Revenue, Total | 193 | 750 | 722 | 952 | 1017 |
| Gross Profit | 1744 | 3604 | 4247 | 6259 | 5049 |
| Total Operating Expense | 671 | 1292 | 1411 | 1801 | 1839 |
| Selling/General/Admin. Expenses, Total | 77 | 121 | 168 | 201 | 268 |
| Research & Development | 401 | 421 | 521 | 648 | 554 |
| Operating Income | 1266 | 3062 | 3558 | 5410 | 4227 |
| Interest Income (Expense), Net Non-Operating | 1 | 0 | 0 | 0 | 3 |
| Other, Net | -7 | 1 | -6 | 0 | -1 |
| Net Income Before Taxes | 1260 | 3063 | 3552 | 5410 | 4229 |
| Net Income After Taxes | 1221 | 2780 | 3333 | 4868 | 3657 |
| Net Income Before Extra. Items | 1221 | 2780 | 3333 | 4868 | 3657 |
| Net Income | 1221 | 2780 | 3333 | 4868 | 3657 |
| Income Available to Common Excl. Extra. Items | 1221 | 2780 | 3333 | 4868 | 3657 |
| Income Available to Common Incl. Extra. Items | 1221 | 2780 | 3333 | 4868 | 3657 |
| Diluted Net Income | 1221 | 2780 | 3333 | 4868 | 3657 |
| Diluted Weighted Average Shares | 430 | 431 | 434 | 431 | 426 |
| Diluted EPS Excluding Extraordinary Items | 2.83953 | 6.45012 | 7.67972 | 11.2947 | 8.58451 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 2.83953 | 6.45012 | 7.67972 | 11.2947 | 8.58451 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 1087.15 | 783.223 | 1563.01 | 1128.8 | 6297.88 | 16071 |
| Cash and Short Term Investments | 1058.14 | 756.029 | 1521.43 | 1103 | 4607.61 | 10727 |
| Cash & Equivalents | 50.08 | 134.859 | 658.364 | 235.876 | 2623.85 | 6848 |
| Short Term Investments | 1008.06 | 621.17 | 863.063 | 867.124 | 1983.76 | 3879 |
| Total Receivables, Net | 17.951 | 16.656 | 30.583 | 16.297 | 1410.53 | 3296 |
| Accounts Receivable - Trade, Net | 13.523 | 13.417 | 12.585 | 5.369 | 1390.56 | 3175 |
| Prepaid Expenses | 11.063 | 9.587 | 10.401 | 8.475 | 232.185 | 531 |
| Other Current Assets, Total | 0 | 0.951 | 0.595 | 1.032 | 1.032 | 76 |
| Total Assets | 1417.16 | 1084.49 | 1962.15 | 1589.42 | 7336.75 | 24669 |
| Property/Plant/Equipment, Total - Net | 81.207 | 139.031 | 211.977 | 287.909 | 387.09 | 1383 |
| Property/Plant/Equipment, Total - Gross | 109.016 | 187.062 | 276.433 | 382.493 | 506.751 | 1735 |
| Accumulated Depreciation, Total | -27.809 | -48.031 | -64.456 | -94.584 | -119.661 | -352 |
| Long Term Investments | 236.569 | 145.851 | 172.99 | 159.987 | 638.848 | 6843 |
| Other Long Term Assets, Total | 12.233 | 16.384 | 14.176 | 12.722 | 12.933 | 372 |
| Total Current Liabilities | 162.802 | 191.461 | 222.803 | 143.115 | 4388.81 | 9128 |
| Accounts Payable | 28.157 | 20.725 | 31.21 | 7.09 | 18.359 | 302 |
| Accrued Expenses | 25.052 | 72.715 | 79.073 | 71.236 | 475.563 | 1518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 109.593 | 98.021 | 112.52 | 64.789 | 3870.56 | 7143 |
| Total Liabilities | 575.31 | 459.193 | 431.908 | 414.612 | 4775.38 | 10524 |
| Total Long Term Debt | 12.5 | 15.687 | 33.489 | 38.689 | 109.874 | 599 |
| Capital Lease Obligations | 12.5 | 15.687 | 33.489 | 38.689 | 109.874 | 599 |
| Other Liabilities, Total | 400.008 | 252.045 | 175.616 | 232.808 | 276.693 | 797 |
| Total Equity | 841.851 | 625.296 | 1530.24 | 1174.81 | 2561.38 | 14145 |
| Preferred Stock - Non Redeemable, Net | 1176.66 | 1176.66 | 0 | |||
| Common Stock | 0.006 | 0.006 | 0.033 | 0.034 | 0.04 | 0 |
| Additional Paid-In Capital | 31.305 | 71.679 | 2538.16 | 2669.43 | 4801.85 | 4211 |
| Retained Earnings (Accumulated Deficit) | -365.718 | -621.893 | -1006.63 | -1496.45 | -2243.52 | 9958 |
| Other Equity, Total | -0.403 | -1.157 | -24 | |||
| Total Liabilities & Shareholders’ Equity | 1417.16 | 1084.49 | 1962.15 | 1589.42 | 7336.75 | 24669 |
| Total Common Shares Outstanding | 324.411 | 324.411 | 328.799 | 336.537 | 398.788 | 403 |
| Unrealized Gain (Loss) | -1.32 | 1.804 | 3.004 | |||
| Redeemable Preferred Stock | 0 | 0 | 0 | |||
| Total Inventory | 46.527 | 1441 | ||||
| Current Port. of LT Debt/Capital Leases | 24.328 | 165 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 11703 | 10969 | 13425 | 16071 | 16350 |
| Cash and Short Term Investments | 7735 | 7990 | 8906 | 10727 | 10115 |
| Cash & Equivalents | 5442 | 5603 | 5550 | 6848 | 5048 |
| Short Term Investments | 2293 | 2387 | 3356 | 3879 | 5067 |
| Total Receivables, Net | 3228 | 2071 | 3199 | 3296 | 3364 |
| Accounts Receivable - Trade, Net | 3210 | 2020 | 3142 | 3175 | 3173 |
| Total Inventory | 494 | 643 | 965 | 1441 | 1942 |
| Prepaid Expenses | 246 | 197 | 261 | 531 | 858 |
| Total Assets | 12694 | 16153 | 20923 | 24669 | 27609 |
| Property/Plant/Equipment, Total - Net | 461 | 898 | 960 | 1383 | 1473 |
| Property/Plant/Equipment, Total - Gross | 596 | 1102 | 1234 | 1735 | 1904 |
| Accumulated Depreciation, Total | -135 | -204 | -274 | -352 | -431 |
| Long Term Investments | 468 | 4207 | 6442 | 6843 | 9171 |
| Other Long Term Assets, Total | 62 | 79 | 96 | 372 | 615 |
| Total Current Liabilities | 8441 | 8840 | 9957 | 9128 | 9238 |
| Accounts Payable | 8 | 77 | 87 | 302 | 199 |
| Accrued Expenses | 760 | 859 | 1098 | 1518 | 1654 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 45 | 159 | 218 | 165 | 160 |
| Other Current Liabilities, Total | 7628 | 7745 | 8554 | 7143 | 7225 |
| Total Liabilities | 8856 | 9449 | 10799 | 10524 | 10534 |
| Total Long Term Debt | 138 | 328 | 238 | 599 | 646 |
| Capital Lease Obligations | 138 | 328 | 238 | 599 | 646 |
| Other Liabilities, Total | 277 | 281 | 604 | 797 | 650 |
| Total Equity | 3838 | 6704 | 10124 | 14145 | 17075 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.0401 | 0.0403 | 0.0405 | 0 | 0.04 |
| Additional Paid-In Capital | 4860 | 4931 | 5003 | 4211 | 3644 |
| Retained Earnings (Accumulated Deficit) | -1023 | 1757 | 5090 | 9958 | 13615 |
| Unrealized Gain (Loss) | 1 | -211 | |||
| Other Equity, Total | -0.0401 | 15.9597 | 30.9595 | -24 | 26.96 |
| Total Liabilities & Shareholders’ Equity | 12694 | 16153 | 20923 | 24669 | 27609 |
| Total Common Shares Outstanding | 401 | 403 | 405 | 403 | 400 |
| Other Current Assets, Total | 68 | 94 | 76 | 71 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -216.211 | -255.916 | -384.734 | -514.021 | -747.064 | 12202 |
| Cash From Operating Activities | 66.734 | -331.484 | -330.865 | -458.968 | 2026.97 | 13620 |
| Cash From Operating Activities | 15.114 | 20.537 | 24.862 | 31.021 | 31.251 | 232 |
| Deferred Taxes | 0.288 | -318 | ||||
| Non-Cash Items | 41.838 | 41.141 | 71.59 | 77.696 | 165.73 | 196 |
| Cash Taxes Paid | 0.905 | 0.398 | 0.294 | 0.416 | 0.572 | 480 |
| Changes in Working Capital | 225.705 | -137.246 | -42.583 | -53.664 | 2577.05 | 1308 |
| Cash From Investing Activities | -648.607 | 417.364 | -373.094 | -14.945 | -1671.93 | -8523 |
| Capital Expenditures | -33.144 | -58.401 | -105.766 | -31.554 | -67.448 | -284 |
| Other Investing Cash Flow Items, Total | -615.463 | 475.765 | -267.328 | 16.609 | -1604.48 | -8239 |
| Cash From Financing Activities | 472.91 | 0.168 | 1226.84 | 51.121 | 2033.19 | -873 |
| Financing Cash Flow Items | -0.633 | 1.241 | 11.635 | 0.971 | 0 | |
| Issuance (Retirement) of Stock, Net | 473.543 | 0.212 | 1217.38 | 50.15 | 2039.41 | -733 |
| Issuance (Retirement) of Debt, Net | 0 | -1.285 | -2.175 | 0 | -6.215 | -140 |
| Net Change in Cash | -108.963 | 86.048 | 522.883 | -422.792 | 2388.24 | 4224 |
| Cash Interest Paid | 8.528 | 14 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1221 | 4001 | 7334 | 12202 | 3657 |
| Cash From Operating Activities | 2971 | 7034 | 10310 | 13620 | 2763 |
| Cash From Operating Activities | 15 | 84 | 154 | 232 | 79 |
| Deferred Taxes | -50 | -72 | -89 | -318 | -146 |
| Non-Cash Items | 35 | 78 | 138 | 196 | 62 |
| Changes in Working Capital | 1750 | 2943 | 2773 | 1308 | -889 |
| Cash From Investing Activities | -180 | -4058 | -7385 | -8523 | -3921 |
| Capital Expenditures | -35 | -65 | -164 | -284 | -132 |
| Other Investing Cash Flow Items, Total | -145 | -3993 | -7221 | -8239 | -3789 |
| Cash From Financing Activities | 26 | 2 | 0 | -873 | -642 |
| Issuance (Retirement) of Stock, Net | 28 | 64 | 96 | -733 | -611 |
| Issuance (Retirement) of Debt, Net | -2 | -62 | -96 | -140 | -31 |
| Net Change in Cash | 2817 | 2978 | 2925 | 4224 | -1800 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Baillie Gifford & Co. | Investment Advisor | 11.6577 | 44786746 | -493277 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.0988 | 27272334 | -205438 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.4308 | 17022247 | -545268 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.7758 | 14506066 | -260514 | 2022-09-30 | LOW |
| Flagship Ventures | Venture Capital | 3.3543 | 12886743 | 0 | 2022-09-30 | LOW |
| Langer (Robert S Jr.) | Individual Investor | 2.996 | 11510060 | 703 | 2022-04-28 | |
| Boston Biotech Ventures, L.L.C. | Corporation | 2.3558 | 9050372 | 0 | 2022-03-01 | LOW |
| OCHA, L.L.C. | Corporation | 1.8233 | 7004880 | -80000 | 2022-03-01 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6263 | 6247811 | -89880 | 2022-09-30 | LOW |
| Theleme Partners LLP | Hedge Fund | 1.5629 | 6004406 | -350000 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.5611 | 5997327 | 2604953 | 2022-09-30 | LOW |
| Coatue Management, L.L.C. | Hedge Fund | 1.4854 | 5706504 | 173 | 2022-09-30 | |
| Bancel (Stephane J) | Individual Investor | 1.4087 | 5411946 | 0 | 2023-02-02 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.2947 | 4974009 | -150991 | 2023-01-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.2263 | 4711101 | 339752 | 2022-09-30 | LOW |
| Banque Pictet & Cie S.A. | Investment Advisor | 0.8021 | 3081437 | 57256 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.7925 | 3044449 | -45668 | 2021-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.6722 | 2582471 | 1461529 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6374 | 2448814 | -119997 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6342 | 2436418 | -44023 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +500000+
Traders
93000+
Active clients monthly
$57000000+
Monthly investing volume
$31000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Moderna, Inc. Company profile
Get all the information you need on the Moderna stock price today with Capital.com’s comprehensive chart.
Moderna (MRNA) is a North American clinical-stage biotechnology company. Headquartered in Cambridge, Massachusetts, it specialises in drug discovery and development, as well as vaccine technologies based on messenger RNA (mRNA). The company is working on therapeutics and vaccines for infectious, autoimmune, immuno-oncology and cardiovascular diseases.
Moderna has a number of strategic partnerships with industry-leading names, such as Vertex Pharmaceuticals (VRTX), AstraZeneca (AZN) and Merck & Co (MRK). In 2020, it also worked with Lonza Group (LONN) and Catalent (CTLT) to manufacture its Covid-19 vaccine candidate mRNA-1273. At the end of 2020, the company had 12 programmes in clinical trials and a total of 23 development candidates.
Moderna shares are listed on the Nasdaq Stock Market under the ticker symbol MRNA. The company is a constituent of the NASDAQ-100 Index.
Stay up-to-date with the latest market news and watch the Moderna share price live at Capital.com.
The company was founded in 2010 as Moderna Therapeutics, with the goal of commercialising the research of stem-cell biologist Derrick Rossi. Apart from Rossi, Moderna’s co-founders were Noubar Afeyan, Robert Langer and Kenneth Chien. In August 2018, the company’s name was changed to Moderna.
In November 2020, Moderna’s Covid-19 vaccine candidate, mRNA-1273, showed preliminary evidence of 94.1 per cent efficacy in preventing the disease in a Phase 3 trial. The results led to its submission for emergency use authorisation in the US, Canada and Europe.
In late November, the EU made a deal with Moderna for up to 160 million doses of its vaccine. In December, the US government exercised its option to buy an additional 100 million doses of Moderna’s mRNA-1273, bringing the confirmed order commitment to 200 million doses.
With Capital.com’s Moderna share price chart, you can not only quickly view the current MRNA stock quote, but also trace the company’s share value in historic terms.
Moderna’s long-awaited initial public offering (IPO) happened in December 2018, with the firm selling 26.3 million shares priced at $23 each. At the time, it was the biggest biotech IPO ever. Moderna raised over $600m, valuing the company at $7.5bn (£5.6bn, €6.2bn).
In 2020, MRNA stock has been one of the US market’s best performers. This was due to rising investor enthusiasm over the company’s promising Covid-19 vaccine candidate. After opening the year at $19.57, the MRNA share price was on a hike, peaking at $94.85 in mid July. Within a month, it had dropped to $54.23, but then the stock gained another upside momentum, with its price surging past $100 on November 16. On December 8, the stock closed the trading day at $169.86, representing a year-to-date gain of nearly 770 per cent.
You can go long or short on the company’s shares and trace all the latest ups and downs of the Moderna Inc. stock price using Capital.com’s proprietary trading platform.
| Industry: | Biotechnology & Medical Research (NEC) |
200 Technology Sq
CAMBRIDGE
MASSACHUSETTS 02139-3578
US
Income Statement
- Annual
- Quarterly
News
Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40
Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech
12:34, 8 February 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:00, 7 February 2023
Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher
Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside
12:41, 7 February 2023
Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps
AUS/USD bounces higher as RBA delivers its 9th rate hike
11:28, 7 February 2023
Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com